The immunotherapy, CAN-2409, in combination with radiation therapy, helped 75.2% patients live without any sign of the cancer ...

Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found ...

A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200% ...

In most countries, prostate cancer incidence and mortality rates decreased or were stable in the most recent five-year period ...

Montell Jordan is advocating for prostate cancer awareness and emphasizing the importance of early detection, particularly ...

Former Chicago Cubs player Ryne Sandberg recently took to social media to share a devastating update regarding his health ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include ...

Candel Therapeutics' CAN-2409 shows a 14.5% improvement in prostate cancer survival. Discover why CADL stock stays a "Buy" ...

Sky Sports is supporting The BIGGER 180 campaign; in the UK, one man dies from prostate cancer every 45 minutes but finding ...

Candel Therapeutics reports phase 3 trial success for CAN-2409 in prostate cancer, showing improved disease-free survival and ...